Alambic Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Alambic Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,220	Closed	-$451K	–	197
2019 Q4	$451K	Sell	1,220 -2,700	-69%	-$952K	0.38%	102
2019 Q3	$1.3M	Sell	3,920 -1,370	-26%	-$447K	0.98%	7
2019 Q2	$1.65M	Sell	5,290 -560	-10%	-$168K	1.02%	5
2019 Q1	$1.79M	Sell	5,850 -2,970	-34%	-$801K	0.73%	26
2018 Q4	$2.05M	Buy	8,820 +6,525	+284%	+$1.75M	0.86%	24
2018 Q3	$718K	Buy	+2,295	New	+$712K	0.57%	56
2017 Q2	–	Sell	-1,100	Closed	-$219K	–	570
2017 Q1	$219K	Hold	1,100	–	–	0.03%	563
2016 Q4	$201K	Buy	+1,100	New	+$188K	0.04%	502

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Alambic Investment Management's BIO Position: Q1 2020 in Review

Alambic Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2020, closing a stake of 1,220 shares — an estimated $451K sold.

Alambic Investment Management first reported a position in BIO in Q4 2016 and held it in 8 quarters. The position peaked at $2.05M in Q4 2018. 406 funds tracked by Wall St. Rank hold BIO as of Q1 2020.

Alambic Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2020 after selling out during the quarter.
Alambic Investment Management sold 1,220 Bio-Rad Laboratories Class A shares in Q1 2020, an estimated $451K.
Alambic Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and held it in 8 quarters.
Alambic Investment Management's Bio-Rad Laboratories Class A position peaked at $2.05M in Q4 2018.
406 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2020.

Based on Alambic Investment Management's 13F filing for Q1 2020, filed 11 May 2020.